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up 2 years for active TB disease. ELISPOT was done in ESRD
patients only.
Results: Compared to the healthy controls, a high prevalence of
LTBI was found in the ESRD patients by TST (62.5%, 95% conﬁ-
dence interval [CI] 43.7–78.9), QFT-G (40.0%, 95% CI 22.7–59.4),
and ELISPOT (46.9%, 95% CI 29.1–65.3). Agreement was moderate
(kappa [κ] = 0.53) for QFT-G and ELISPOT but only slight between
TST and QFT-G (κ = 0.25) and fair between TST and ELISPOT (κ
= 0.32). ESRD (p = 0.03) and diabetes mellitus (p = 0.04) were
signiﬁcant risk factors for QFT-G positivity on the multivariable
analysis. The overall rate of active TB was 1.66 cases per 100
person-years (pys), with the rate higher in patients with ESRD
(3.53 per 100 pys) and those with positive (3.40 per 100 pys)
and indeterminate QFT results (30.16 per 100 pys), although the
difference was not statistically signiﬁcant. Sensitivity, speciﬁcity,
and positive and negative predictive values of QFT-G for active
TB was 100%, 62.1%, 8.3% and 100%.
Conclusion: This pilot study is the ﬁrst to compare QFT-G,
ELISPOT, and TST in ESRD patients on hemodialysis and demon-
strates a high prevalence of LTBI in this population. In our
study, the QFT-G was the more accurate method for identifying
those truly infected with Mycobacterium tuberculosis, even in
BCG-vaccinated individuals.
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To study the interaction between syphilis and HIV infections
to enhance detection of cases and improve clinical care for
HIV-syphilis coinfected patients.
A review of published literature showed syphilis is associated with
increased risk for HIV sexual transmission and acquisition. HIV
might shift the clinical manifestations of syphilis, rendering le-
sions more apparent, and accelerate the progression of syphilitic
disease. Among HIV-infected persons, atypical and/or multiple
chancres can occur or primary syphilitic lesions might be absent.
Secondary syphilis, particularly acute syphilitic meningitis, can
resemble acute primary HIV infection: constitutional symptoms
with non- focal CNS signs and symptoms and CSF abnormalities
(lymphocytic pleocytosis and mildly elevated CSF protein), are
common. Responses to non-treponemal serologic tests (VDRL,
RPR) can be atypical (higher, lower, delayed) amongst HIV- in-
fected patients with early syphilis. There is, however, little data
that treponemal tests (EIA, FTA, TPPA) perform differently. On
the other hand, it is unknown whether there is difference in prog-
nostic signiﬁcance of CSF abnormalities between HIV- infected
and – noninfected persons. Some recommended CSF examination
for all HIV- infected patients with syphilis regardless of stage, in
particular for RPR ≥ 1:32 or CD4 < 350 per uL. Penicillin remains
treatment of choice for syphilis regardless of HIV status. Most
HIV- infected persons with early syphilis respond to standard
benzathine penicillin although some recommend two additional
weekly benzathine penicillin injections. The beneﬁt of latter
approach remains unknown. Retreatment of early stage syphilis
should be considered when there is sustained 4-fold increase in
serum nontreponemal titres (SNT) after an intial reduction after
treatment, or when there are persistent/recurring clinical signs
and symptoms. Some recommend retreating early syphilis for
those who do not have a 4- fold decrease in SNT at 6- 12 months
after treatment.
Occurrence of syphilis in HIV- infected patient is an indication
of high- risk behaviour and should prompt intensive counseling,
referral for behaviour intervention, screening and treatment for
syphilis as well as for other sexually transmitted diseases.
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Antiretroviral therapy (ART) for HIV-1 infected patients has been
rapidly scaled up worldwide in the last decade. In Thailand, the
national policy of providing free access to ART has been imple-
mented since 2002. Successful outcomes are not always observed
and HIV-1 drug resistance is a major cause of treatment failure.
The emergence and transmission of drug-resistant HIV-1 infection
inevitably follows the increasing use of ART, which reduces the
efﬁcacy of the ﬁrst-line ART. This suggests that scaling up of
access to ART in Thailand is becoming vulnerable to be at risk of
the HIV-1 drug resistance problem. Both primary and secondary
drug resistance have been observed. In Thailand, a recent pub-
lished data has shown 2% of HIV-1 drug resistance among persons
with recent infection, which increased from 0% in 2003 to 5.2% in
2006. All seven patients with viral resistance had sexual partner
with low adherence and treatment failure with NNRTI-based reg-
imen. This suggests that HIV-1 drug resistance was transmitted
among couples. Intervention of prevention program, i.e. 100%
condom campaign, needs to be re-strengthened and emphasized.
The prevalence of primary resistance depends on the character-
istics of study population especially duration of HIV-1 infection.
Another study had found baseline antiretroviral drug resistance
mutations in 4% of Thai HIV-1 infected patients with unknown
duration of HIV-1 infection. Nevertheless, data of primary HIV-1
drug resistance in Thailand is still limited. A study to determine
the prevalence and risk factors of primary HIV-1 drug resistance,
using surveillance drug resistance mutations recommended for
surveillance of transmitted HIV-1 drug resistance by WHO in
2009, is ongoing in Thailand. To date, the implementation HIV-1
resistance testing for treatment naïve patients in Thailand is not
currently feasible because of the high cost and cost-effectiveness
issue. However, selected group of patients with high risk of pri-
mary HIV-1 drug resistance should be considered.
Secondary HIV-1 drug resistance has become common in Thailand
after rapid scaling up of ART. Resistance mutations to NRTIs
and NNRTIs are the most common form, reﬂecting local pre-
scription patterns. Thai ART guidelines have recommended a
ﬁxed-dose combination of stavudine/zidovudine, lamivudine and
nevirapine (d4T/3TC/NVP or AZT/3TC/NVP) as preferred initial
regimens. A prospective cohort study in patients who were ini-
tiated d4T/3TC/NVP has shown that 9.3% of patients developed
HIV-1 drug resistance within 3 years. Another study of geno-
typic resistance testing conducted among HIV-1 infected patients
who experienced treatment failure with their ﬁrst antiretrovi-
ral regimen of d4T/3TC/NVP during 2003-2005 in Thailand has
demonstrated that late detection of virological failure is asso-
ciated with extensive HIV-1 drug resistance and limited options
for a second-line regimen. In resource-limited settings where
availability of antiretroviral agents is limited, strategies for pre-
vention of HIV-1 resistance are crucial. The adherence to ART
is the key of successful treatment. Early detection of virologi-
cal failure with regular monitoring of treatment responses may
provide more options and better treatment outcomes.
